Overview
Compare with Virtuix Holdings Inc., INTERLINK ELECTRONICS INC or Wetouch Technology Inc., or pick any stock.
- TickerAIMD on Nasdaq1
- IndustryComputer Peripheral Equipment, NEC1
- HeadquartersHouston, Texas1
- Incorporated inTX2
- Business address3050 Post Oak Blvd,, Suite 510-T80, Houston, Tx 770562
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
AI Nose to address this gap by translating complex scent signals into a structured, machine-readable data format.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
82.9%Gross margin5
-11268.3%Operating margin5
-11897.0%Net margin5
499.0%Revenue growth, 20255
-195.3%Return on equity5
-$4.6MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$21.2K
- Research and development55¢$7.7M
- Selling, general and admin45¢$6.3M
- Income tax0¢$800
Out of $124.2K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $124.2K | $20.7K |
| Cost of revenues | -$21.2K | -$52.6K |
| Gross profit (loss) | $102.9K | -$31.9K |
| Research and development expenses (including amounts for related party of $947,084 and $1,418,887 for the years ended December 31, 2025 and 2024, respectively) | $7.7M | $8.4M |
| Selling, general and administrative expenses | $6.3M | $5.4M |
| Total operating expenses | $14.1M | $13.8M |
| Loss from operations | -$14.0M | -$13.8M |
| Interest expense | -$711.9K | -$616.5K |
| Issuance cost of senior secured convertible note measured at fair value | -$308.3K | |
| Fair value change of senior secured convertible note | -$275.6K | |
| Other income (expenses), net | -$67.9K | $179.3K |
| Total non-operating expenses, net | -$779.8K | -$1.0M |
| Net loss before income taxes | -$14.8M | -$14.9M |
| Provision for income taxes | $800 | $800 |
| Net loss | -$14.8M | -$14.9M |
| Net loss per common share - basic | -$3.46 | -$7.82 |
| Net loss per common share - diluted | -$3.46 | -$7.82 |
| Weighted-average shares used in computing net loss per common share-basic | 4.3M shares | 1.9M shares |
| Weighted-average shares used in computing net loss per common share-diluted | 4.3M shares | 1.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-11-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $417.4K | $3.9M | ||
| Accounts receivable | $22 | $56 | ||
| Inventory, net | $295.6K | $143.8K | ||
| Other current assets | $425.9K | $301.1K | ||
| Total current assets | $1.1M | $4.3M | ||
| Intangible assets, net | $19.2M | $23.7M | ||
| Property and equipment, net | $343.3K | $559.6K | ||
| Other assets | $163.0K | $174.4K | ||
| Total assets | $20.9M | $28.8M | ||
| Accrued expenses and other current liabilities | $728.7K | $848.6K | ||
| Total current liabilities | $1.1M | $4.0M | ||
| Convertible notes payable - noncurrent (including amounts to related party of $11,000,000 and $9,000,000 as of December 31, 2025 and 2024, respectively) | $11.0M | $9.0M | ||
| Other long-term liabilities | $1.2M | $348.9K | ||
| Total liabilities | $13.3M | $13.3M | ||
| Common stock, $0.01 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 6,982,675 shares and 3,085,477 shares issued and 5,882,675 and 3,085,477 shares outstanding as of December 31, 2025 and 2024, respectively | $69.8K | $30.9K | ||
| Treasury stock, at cost (1,160,000 and nil shares held as of December 31, 2025 and 2024, respectively) | -$2.0M | |||
| Additional paid-in capital | $77.2M | $68.6M | ||
| Accumulated deficit | -$67.5M | -$52.7M | ||
| Accumulated other comprehensive loss - translation adjustment | -$249.3K | -$409.5K | ||
| Total stockholders equity | $7.6M | $15.5M | $24.4M | |
| Total liabilities and stockholders equity | $20.9M | $28.8M | ||
| Contract liabilities current | $350.0K | $106.3K | ||
| Convertible notes payable current | $3.0M | |||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 7.0M shares | 3.1M shares | ||
| Common stock, shares outstanding | 5.9M shares | 3.1M shares | ||
| Stock issued in exchange for subsidiary shares | 1.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-11-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $417.4K | $3.9M | ||
| Accounts receivable | $22 | $56 | ||
| Inventory, net | $295.6K | $143.8K | ||
| Other current assets | $425.9K | $301.1K | ||
| Total current assets | $1.1M | $4.3M | ||
| Intangible assets, net | $19.2M | $23.7M | ||
| Property and equipment, net | $343.3K | $559.6K | ||
| Other assets | $163.0K | $174.4K | ||
| Total assets | $20.9M | $28.8M | ||
| Accrued expenses and other current liabilities | $728.7K | $848.6K | ||
| Total current liabilities | $1.1M | $4.0M | ||
| Convertible notes payable - noncurrent (including amounts to related party of $11,000,000 and $9,000,000 as of December 31, 2025 and 2024, respectively) | $11.0M | $9.0M | ||
| Other long-term liabilities | $1.2M | $348.9K | ||
| Total liabilities | $13.3M | $13.3M | ||
| Common stock, $0.01 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 6,982,675 shares and 3,085,477 shares issued and 5,882,675 and 3,085,477 shares outstanding as of December 31, 2025 and 2024, respectively | $69.8K | $30.9K | ||
| Treasury stock, at cost (1,160,000 and nil shares held as of December 31, 2025 and 2024, respectively) | -$2.0M | |||
| Additional paid-in capital | $77.2M | $68.6M | ||
| Accumulated deficit | -$67.5M | -$52.7M | ||
| Accumulated other comprehensive loss - translation adjustment | -$249.3K | -$409.5K | ||
| Total stockholders equity | $7.6M | $15.5M | $24.4M | |
| Total liabilities and stockholders equity | $20.9M | $28.8M | ||
| Contract liabilities current | $350.0K | $106.3K | ||
| Convertible notes payable current | $3.0M | |||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 7.0M shares | 3.1M shares | ||
| Common stock, shares outstanding | 5.9M shares | 3.1M shares | ||
| Stock issued in exchange for subsidiary shares | 1.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$14.8M | -$14.9M |
| Depreciation and amortization | $4.8M | $4.8M |
| Share-based compensation expense | $1.7M | $3.5M |
| Stock issued for special stock bonus | $2.7M | $89.0K |
| Issuance cost of senior secured convertible note measured at fair value | $308.3K | |
| Issuance of common stock for consulting services | $225.0K | |
| Changes in fair value of senior secured convertible note | $275.6K | |
| Gain on disposal of property, plant and equipment | -$1.1K | |
| Accounts receivable | $34 | $399 |
| Inventory | -$151.8K | $23.8K |
| Other current assets | -$123.1K | $118.4K |
| Accrued expenses and other current and long-term liabilities | $1.0M | -$105.6K |
| Net cash used in operating activities | -$4.6M | -$5.8M |
| Purchase of property and equipment | -$34.6K | -$21.3K |
| Decrease (Increase) in refundable deposits and other assets | $32.3K | -$104.0K |
| Net cash used in investing activities | -$2.2K | -$125.3K |
| Proceeds from convertible notes payable- noncurrent, related party | $9.0M | |
| Proceeds from senior secured convertible notes payable | $875.0K | |
| Proceeds from at-the-market offering, net of issuance costs | $2.0M | |
| Repayment of convertible notes payable | -$1.0M | |
| Repayment of senior secured convertible notes payable | -$1.4M | |
| Repayment of other notes payable, related party | -$312.0K | |
| Payment of issuance cost of senior secured convertible note measured at fair value | -$97.5K | |
| Fractional shares paid out in cash for the reverse stock split | -$260 | |
| Net cash provided by financing activities | $1.0M | $8.0M |
| Effect from foreign currency exchange | $132.9K | -$84.9K |
| Net (decrease) increase in cash and cash equivalents | -$3.5M | $2.0M |
| Cash paid for interest | $32 | $21.7K |
| Cash paid for income taxes | $800 | $800 |
| Issuance of common stock for consulting services | $225.0K | |
| Conversion of senior secured convertible notes to common stock | $2.4M | |
| Receivable from disposal of property, plant and equipment | $1.7K | |
| Issuance of common stock for exchanging subsidiary company shares | $2.0M |
No quarter-by-quarter statement was filed.
Corporate structure
Ainos, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Ainos, Inc.
- AINOS INC Filed SCHEDULE 13D/A on Ainos, Inc., latest Apr 17, 2026 (15 filings since Dec 13, 2021)
- Chung-Jung Tsai Filed SCHEDULE 13D/A on Ainos, Inc., latest Apr 17, 2026 (2 filings since Nov 28, 2025)
- Ting-Chuan Lee Filed SCHEDULE 13D/A on Ainos, Inc., latest Apr 17, 2026 (3 filings since Apr 11, 2025)
- ASE Technology Holding Co., Ltd. Filed SCHEDULE 13D/A on Ainos, Inc., latest Apr 15, 2026 (3 filings since May 8, 2024)
- Taiwan Carbon Nano Technology Corp Filed SCHEDULE 13D/A on Ainos, Inc., latest Jan 30, 2026 (3 filings since Aug 21, 2024)
- ScentAI Inc. Filed SCHEDULE 13D on Ainos, Inc., latest Jan 27, 2026
- Chun-Hsien Tsai Filed SCHEDULE 13D/A on Ainos, Inc., latest Nov 28, 2025 (2 filings since Apr 11, 2025)
- Ainos, Inc. Houston, Texas
- ScentAI Inc. Subsidiary · Texas, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Ainos, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.8M5 Dec 31, 2025 | $1.7M5 Dec 31, 2024 | +4.2% |
| Accumulated depreciation | $1.4M5 Dec 31, 2025 | $1.1M5 Dec 31, 2024 | +25.5% |
| Property and equipment, net | $343.3K5 Dec 31, 2025 | $559.6K5 Dec 31, 2024 | −38.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $417.4K5 Dec 31, 2025 | $3.9M5 Dec 31, 2024 | −89.3% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $19.2M5 Dec 31, 2025 | $23.7M5 Dec 31, 2024 | −19.0% |
| Finite-lived intangibles, gross | $39.4M5 Dec 31, 2025 | $39.4M5 Dec 31, 2024 | 0% |
| Accumulated amortization | $20.1M5 Dec 31, 2025 | $15.6M5 Dec 31, 2024 | +28.9% |
| Finite-lived intangibles, net | $19.2M5 Dec 31, 2025 | $23.7M5 Dec 31, 2024 | −19.0% |
| Patents, net | $39.1M5 Dec 31, 2025 | $39.1M5 Dec 31, 2024 | 0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $295.6K5 Dec 31, 2025 | $143.8K5 Dec 31, 2024 | +105.6% |
| Raw materials | $118.3K5 Dec 31, 2025 | $74.9K5 Dec 31, 2024 | +58.0% |
| Work in process | $108.3K5 Dec 31, 2025 | $1.1K5 Dec 31, 2024 | +9473.7% |
| Finished goods | $69.0K5 Dec 31, 2025 | $67.8K5 Dec 31, 2024 | +1.8% |
Properties, in its own words
Our administrative offices are located at Houston, Texas and in Taiwan. Our product development facility is in Taiwan.
Item 2 of the 10-K filed Mar 30, 2026.4
Leadership
Who has led Ainos, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2010201520202025
- Chief executive officerChung-Yi Tsai Apr 12, 2023 to Apr 12, 202313
- Chief executive officerChun-Hsien Tsai Apr 28, 2021 to Apr 12, 202314
- Chief executive officerJoseph M. Cummins May 19, 2006 to Oct 19, 201115
- ChairChung-Yi Tsai Apr 12, 2023 to Apr 12, 202313
- ChairChun-Hsien Tsai Apr 28, 2021 to Apr 12, 202314
- ChairJoseph M. Cummins May 19, 2006 to Oct 19, 201115
- PresidentChung-Yi Tsai Apr 12, 2023 to Apr 12, 202313
- PresidentChun-Hsien Tsai Oct 26, 2022 to Apr 12, 202316
- PresidentJoseph M. Cummins May 19, 2006 to Sep 18, 200615
- Chief financial officerHsin-Liang Christopher Lee Mar 19, 2024 to now17
- Chief financial officerMeng Lin Sung Jun 2, 2023 to Feb 20, 202418
- Chief financial officerHui-Lan Wu Jan 6, 2022 to Jul 5, 202319
- Chief financial officerChun-Hsien Tsai Apr 28, 2021 to Apr 28, 202114
- Chief financial officerBernard H. Cohen Sep 15, 2010 to Oct 31, 201820
- Chief financial officerGary Wayne Coy Nov 28, 2006 to Sep 3, 200921
Board members and other officers (18)
- E.V.P. OF OPERATIONSLawrence K. Lin Nov 28, 2023 to Feb 20, 202422
- Vice PresidentBernard H. Cohen Apr 3, 2019 to Jun 3, 201923
- VP, Clinical & Regulatory AffaMartin Joseph Cummins Feb 2, 2007 to Dec 17, 201024
- Board memberPao-Sheng Wei Jun 30, 2022 to now25
- Board memberChung-Jung Tsai Apr 28, 2021 to now26
- Board memberChung-Yi Tsai Apr 28, 2021 to now27
- Board memberHsiu-Chen Chiu Apr 28, 2021 to Dec 29, 202128
- Board memberTing-Chuan Lee Apr 28, 2021 to now29
- Board memberWen-Han Chang Apr 28, 2021 to now30
- Board memberChun-Hsien Tsai Dec 21, 2021 to Jul 28, 202231
- Board memberTibbits Paul Feb 2, 2011 to Jun 4, 201232
- Board memberMarian Tibbits Apr 20, 2011 to Apr 20, 201133
- Board memberGary Wayne Coy Feb 23, 2009 to Feb 23, 200934
- Board memberR. Ulie Thomas Feb 2, 2007 to Aug 1, 200735
- Board memberJames A. Page Dec 27, 2007 to Sep 16, 201036
- Board memberMartin Joseph Cummins Dec 27, 2007 to Dec 27, 200737
- Board memberDennis Dean Moore Oct 4, 2006 to Jun 21, 201238
- Board memberJoseph M. Cummins Oct 30, 2006 to Jun 7, 201139
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ScentAI Inc. Texas3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- AMARILLO BIOSCIENCES INCMay 30, 1996 to Mar 30, 20212
Timeline
- Sep 28, 20268-K Entered a material agreement; Regulation FD disclosure40
- Aug 3, 20268-K Results of operations41
- Jul 10, 20268-K Change of auditor42
- Jul 9, 20268-K New debt or obligation43
- May 13, 20268-K Results of operations44
- Mar 30, 20268-K Results of operations45
- Jan 6, 20268-K Other events46
- Jan 5, 20268-K Regulation FD disclosure47
- Dec 31, 20258-K Unregistered sale of shares48
- Nov 13, 20258-K Results of operations; Shareholder vote49
- Oct 17, 20258-K Entered a material agreement50
- Sep 8, 20258-K Other events51
- Apr 12, 2023New chief executive Chung-Yi Tsai becomes CEO13
- Apr 28, 2021New chief executive Chun-Hsien Tsai becomes CEO14
- May 19, 2006New chief executive Joseph M. Cummins becomes CEO15
Calendar
Coming up
- Nov 12, 2026Reports results for the quarter ending Sep/202652
When it reported results
- Aug 3, 2026Reported quarterly or annual results41
- May 13, 2026Reported quarterly or annual results44
- Mar 30, 2026Reported quarterly or annual results45
- Nov 13, 2025Reported quarterly or annual results49
- Aug 13, 2025Reported quarterly or annual results53
- May 12, 2025Reported quarterly or annual results54
- Mar 7, 2025Reported quarterly or annual results55
- Aug 5, 2024Reported quarterly or annual results56
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
312 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 71 major events, 129 insider forms, 29 large holders, 60 other. The latest 20:
- Sep 28, 20268-K EDGAR
- Aug 3, 20268-K EDGAR
- Aug 3, 202610-Q EDGAR
- Jul 24, 2026424B5 EDGAR
- Jul 10, 20268-K EDGAR
- Jul 9, 20268-K EDGAR
- Jun 9, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 1, 20264 EDGAR
- May 29, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 26, 20264 EDGAR
- May 20, 20264 EDGAR
- May 13, 202610-Q EDGAR
- May 13, 20268-K EDGAR
- May 7, 20264 EDGAR
- May 1, 20264 EDGAR
- Apr 17, 2026SCHEDULE 13D/A EDGAR
The 312 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
41 open-market trades by officers, directors and large owners since October 2021: 16 buys and 25 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | chiang yao-chungDirector | Buy | 3,500 | $2.05 | $7.2K | Form 4 |
| Jun 3, 2026 | chiang yao-chungDirector | Buy | 2,000 | $2.13 | $4.3K | Form 4 |
| May 28, 2026 | chiang yao-chungDirector | Buy | 250 | $2.30 | $575 | Form 4 |
| May 27, 2026 | chiang yao-chungDirector | Buy | 2,000 | $2.00 | $4.0K | Form 4 |
| May 26, 2026 | lee ting-chuanDirector | Sale | 109,988 | $1.90 | $209.0K | Form 4 |
| May 26, 2026 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 41,000 | $2.36 | $96.8K | Form 4 |
| May 26, 2026 | TSAI CHUN-JUNGDirector | Sale | 27,718 | $1.87 | $51.8K | Form 4 |
| May 22, 2026 | TSAI CHUN-JUNGDirector | Sale | 1,082 | $1.55 | $1.7K | Form 4 |
| May 22, 2026 | lee ting-chuanDirector | Sale | 9,302 | $1.57 | $14.6K | Form 4 |
| May 21, 2026 | lee ting-chuanDirector | Sale | 9,000 | $1.56 | $14.0K | Form 4 |
| May 19, 2026 | chiang yao-chungDirector | Buy | 2,200 | $1.68 | $3.7K | Form 4 |
| May 18, 2026 | chiang yao-chungDirector | Buy | 500 | $1.65 | $825 | Form 4 |
| May 5, 2026 | chiang yao-chungDirector | Buy | 129 | $1.70 | $219 | Form 4 |
| Apr 30, 2026 | chiang yao-chungDirector | Buy | 200 | $1.68 | $336 | Form 4 |
| Apr 29, 2026 | chiang yao-chungDirector | Buy | 100 | $1.75 | $175 | Form 4 |
| Jan 28, 2026 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 46,000 | $2.17 | $99.8K | Form 4 |
| Jan 9, 2026 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 431 | $1.86 | $802 | Form 4 |
| Jan 8, 2026 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 850 | $1.80 | $1.5K | Form 4 |
| Oct 6, 2025 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 7,000 | $3.59 | $25.1K | Form 4 |
| Oct 2, 2025 | Taiwan Carbon Nano Technology Corp10% owner | Sale | 2,000 | $3.59 | $7.2K | Form 4 |
All 41 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- AINOS INCSCHEDULE 13D/A, 15 filings Dec 13, 2021 to Apr 17, 202657
- Chung-Jung TsaiSCHEDULE 13D/A, 2 filings Nov 28, 2025 to Apr 17, 202658
- Ting-Chuan LeeSCHEDULE 13D/A, 3 filings Apr 11, 2025 to Apr 17, 202659
- ASE Technology Holding Co., Ltd.SCHEDULE 13D/A, 3 filings May 8, 2024 to Apr 15, 202660
- Taiwan Carbon Nano Technology CorpSCHEDULE 13D/A, 3 filings Aug 21, 2024 to Jan 30, 202661
- ScentAI Inc.SCHEDULE 13D, 1 filing Jan 27, 202662
- Chun-Hsien TsaiSCHEDULE 13D/A, 2 filings Apr 11, 2025 to Nov 28, 202563
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2024 | Chun-Hsien TsaiPresident & Chief Executive Officer | 55 | $122.5K | $301.5K64 |
| 2024 | Hsin-Liang LeeChief Financial Officer | 54 | $79.9K | $93.6K64 |
| 2024 | Lawrence K. LinEVP of Operations | $84.0K64 | ||
| 2024 | Meng-Lin SungFormer Chief Financial Officer | $21.6K | $30.9K64 | |
| 2023 | Chun-Hsien TsaiPresident & Chief Executive Officer | 55 | $95.9K | $1.3M64 |
| 2023 | Meng-Lin SungFormer Chief Financial Officer | $57.4K | $286.0K64 | |
| 2023 | Lawrence K. LinEVP of Operations | $144.0K | $158.8K64 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Geode Capital Management, LLC | 44,086 | $85.5K | 0.0% | −8,988 |
| Keystone Financial Group | 25,550 | $49.6K | 0.0% | +11,000 |
| Vanguard Capital Management LLC | 16,024 | $31.1K | 0.0% | +6,743 |
| Mariner, LLC | 15,800 | $30.7K | 0.0% | −15,000 |
| Vanguard Fiduciary Trust Co | 14,169 | $27.5K | 0.0% | No change |
| Jane Street Group, LLC | 11,504 | $22.3K | 0.0% | New |
| UBS Group AG | 4,592 | $8.9K | 0.0% | +4,590 |
| Tower Research Capital LLC (TRC) | 3,157 | $6.1K | 0.0% | −1,284 |
| BlackRock, Inc. | 3,065 | $5.9K | 0.0% | No change |
| Seneschal Advisors, LLC | 1,800 | $3.5K | 0.0% | No change |
| Steward Partners Investment Advisory, LLC | 1,208 | $2.3K | 0.0% | No change |
| Citigroup Inc | 177 | $343 | 0.0% | −324 |
| Caitong International Asset Management Co., Ltd | 93 | $180 | 0.0% | New |
| Hrt Financial LP | 32,008 | $62 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Ainos, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAinos, Inc.1
- CIK0001014763
- Employer ID (EIN)75-19743524
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
- Incorporated inTexas4
- Fiscal year endsDecember 311
- Industry code (SIC)3577 Computer Peripheral Equipment, NEC1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address3050 Post Oak Blvd,, Suite 510-T80, Houston, TX 770561
- Phone(281) 898-65861
- Shares outstanding7,384,073 as of Aug 3, 202612
- Public float$4.4M as of Jun 30, 20254
- AuditorYCM CPA INC, Irvine, California PCAOB ID 6871; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMay 23, 19961
- Filings1,022 in all: 4 (490), 8-K (133), 10-Q (57), 10QSB (35), 3 (22), S-8 (19), 10-K (18), 4/A (18)1
All 54 form types
UPLOAD (17), CORRESP (16), NT 10-Q (14), SCHEDULE 13D/A (14), SC 13D/A (13), NT 10-K (12), SC 13D (12), 10KSB (10), S-1/A (9), EFFECT (8), D (7), DEF 14A (7), 10-Q/A (6), 10QSB/A (6), DEF 14C (5), PRE 14A (5), PRE 14C (5), S-1 (5), D/A (4), REGDEX (4), SC 13G (4), SCHEDULE 13D (4), 10-K/A (3), 424B5 (3), 8-K/A (3), ARS (3), PRER14A (3), 10KSB/A (2), 10KSB40 (2), 424B3 (2), 8-A12G (2), CT ORDER (2), DEFA14A (2), S-3 (2), S-8 POS (2), SB-2/A (2), 10KSB40/A (1), 3/A (1), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), POS AM (1), S-3/A (1), SB-2 (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Mar 30, 2026
Quarterly report (10-Q) Aug 3, 2026
Proxy statement (DEF 14A) Oct 1, 2025
Latest 8-K (8-K) Sep 28, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock | AIMD | The Nasdaq Stock Market LLC |
| Common Stock Purchase Warrants | AIMDW | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Ainos, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 53 risks under these headings, as written.4
- Risks related to our limited operating history, financial position, and need for additional capital
- We have a history of operating losses that are expected to continue for the foreseeable future, and we are unable to predict the extent of future losses, or whether we will generate significant revenues or achieve or sustain profitability.
- We have generated very little revenue from product sales and may never become profitable.
- We need to raise additional capital to operate our business. If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development.
- We may be unable to access the capital markets, and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.
- Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below expectations.
- Risks related to product development and regulatory process
- AI Nose is a developing platform, and we may be unable to successfully generate meaningful revenue.
- The market for AI-enabled scent digitization and SmellTech solutions may not develop as we expect.
- AI Nose may fail to achieve acceptable accuracy, reliability, or performance across use cases and environments.
- Our AI Nose platform may contain undetected errors, defects, or limitations that could impair adoption or result in liability.
- The performance of AI Nose depends on data collection and model training, which may be insufficient or ineffective.
The other 42 risks
- Customers may be unwilling or unable to integrate AI Nose into existing systems or workflows.
- Expansion into industrial and other non-healthcare environments may expose AI Nose to new and unforeseen risks.
- Our AI Nose platform is highly technical and may contain undetected errors, which could cause harm to our reputation and adversely affect our business.
- We are early in our development efforts of POCT and VELDONA candidates, and our business is dependent on the successful development of our current and future POCT and VELDONA candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.
- Clinical product development involves a lengthy and expensive process, with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current and future product candidates, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our business, financial condition, results of operations and prospects.
- We and our collaboration partners have conducted and intend to conduct clinical trials for selected product candidates at sites outside the United States, and for any of our product candidates for which we seek approval in the United States, the FDA may not accept data from trials conducted in such locations or may require additional U.S.-based trials.
- Our long-term prospects depend in part upon discovering, developing and commercializing additional products, including POCT and VELDONA candidates, which may fail in development or suffer delays that adversely affect their commercial viability.
- Even if we complete the necessary nonclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain, which may prevent us or any of our future collaboration partners from obtaining approvals for the commercialization of our current product candidates and any other product candidate we develop.
- Even if a current or future product candidate, including AI Nose, POCT and VELDONA, receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- The total addressable market opportunity for our current and future products may be much smaller than we estimate.
- We may not obtain approval for our product candidates in any jurisdictions.
- Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.
- Any disruption in our research and development facility could adversely affect our business, financial condition and results of operations.
- Our business and operations would be adversely affected in the event that our computer systems or those of our partners, contract research organizations, contractors, consultants or other third parties we work with were to suffer system failures, cyber-attacks, loss of data or other security incidents.
- Risks related to reliance on third parties
- Our reliance on third-party components and cloud infrastructure could disrupt AI Nose operations, and any errors, disruption, performance problems, or failure in their or our operational infrastructure could adversely affect our business, financial condition, and results of operations.
- We rely on the availability of licenses to third-party technology that may be difficult to replace or that may cause errors or delay implementation of our software and services should we not be able to continue or obtain a commercially reasonable license to such technology.
- We rely on third parties to manufacture our product and product candidates, and we intend to rely on third parties which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
- We currently have limited marketing capabilities. If we are unable to expand sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.
- Our employees, independent contractors, consultants, commercial or strategic partners, principal investigators or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.
- We may form or seek strategic partnerships in the future, and we may not realize the benefits of such alliances or licensing arrangements.
- Risks related to intellectual property, patents, and data privacy
- Issues in the use of AI in our software may result in reputational harm or liability.
- Intellectual property rights vary across foreign jurisdictions, and we may not be able to protect our intellectual property rights throughout the world.
- If we and our collaborators are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents directed towards our technology and product candidates could be found invalid or unenforceable if challenged.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.
- We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
- Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Risks related to our business
- We will need to increase the size of our Company and may not effectively manage our growth.
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- As we are actively involved in marketing VELDONA Pet supplements within a fiercely competitive industry, any inability to effectively compete may adversely impact our operational results.
- The point-of-care testing (“POCT”) market is extremely competitive and rapidly evolving, making it difficult to evaluate our business and future prospects.
- Research and development of drug candidates such as VELDONA is extremely expensive and complex, and it’s difficult to evaluate the likelihood of the outcome of clinical trials, regulatory approvals, and our business and future prospects.
- If we fail to develop and maintain our brand, or the quality of our products that customers have come to expect, our business could suffer.
- Our business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of epidemics, including but not limited to COVID-19.
- Our business activities are subject to the Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, including Taiwan, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
- An active trading market for our common stock may not develop, and the market price of our common stock and warrants could be volatile.
- We do not intend to pay dividends for the foreseeable future, and, as a result, our ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
- We have acquired, and may in the future acquire, assets and technologies as part of our business strategy. If we acquire companies or technologies in the future, they could prove difficult to integrate, disrupt our business, dilute stockholder value, and adversely affect our operating results and the value of our common stock.
- Any failure to maintain effective internal control over financial reporting could harm us.
- Our issuance of additional capital stock in connection with financings, acquisitions, investments, our 2023 Stock Incentive Plan or otherwise will dilute all other stockholders.
Legal proceedings
There are currently no legal proceedings involving the Company.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAinos, Inc. filings on SEC EDGAR
- 2SEC EDGARAinos, Inc. filings on SEC EDGAR
- 3
- 4
- 5SEC EDGARAinos, Inc. 10-K for fiscal 2025
- 6SEC EDGARAinos, Inc. 10-K for fiscal 2019
- 7SEC EDGARAinos, Inc. 10-K for fiscal 2020
- 8SEC EDGARAinos, Inc. 10-K for fiscal 2021
- 9SEC EDGARAinos, Inc. 10-K for fiscal 2022
- 10SEC EDGARAinos, Inc. 10-K for fiscal 2023
- 11SEC EDGARAinos, Inc. 10-Q for fiscal 2026
- 12SEC EDGARAinos, Inc. 10-Q for fiscal 2026
- 13
- 14
- 15
- 16SEC EDGARChun-Hsien Tsai, President
- 17
- 18
- 19SEC EDGARHui-Lan Wu, Chief financial officer
- 20
- 21
- 22
- 23SEC EDGARBernard H. Cohen, Vice President
- 24
- 25SEC EDGARPao-Sheng Wei, Board member
- 26SEC EDGARChung-Jung Tsai, Board member
- 27SEC EDGARChung-Yi Tsai, Board member
- 28SEC EDGARHsiu-Chen Chiu, Board member
- 29SEC EDGARTing-Chuan Lee, Board member
- 30SEC EDGARWen-Han Chang, Board member
- 31SEC EDGARChun-Hsien Tsai, Board member
- 32SEC EDGARTibbits Paul, Board member
- 33SEC EDGARMarian Tibbits, Board member
- 34SEC EDGARGary Wayne Coy, Board member
- 35SEC EDGARR. Ulie Thomas, Board member
- 36SEC EDGARJames A. Page, Board member
- 37SEC EDGARMartin Joseph Cummins, Board member
- 38SEC EDGARDennis Dean Moore, Board member
- 39SEC EDGARJoseph M. Cummins, Board member
- 40
- 41SEC EDGARResults of operations
- 42SEC EDGARChange of auditor
- 43SEC EDGARNew debt or obligation
- 44SEC EDGARResults of operations
- 45SEC EDGARResults of operations
- 46SEC EDGAROther events
- 47SEC EDGARRegulation FD disclosure
- 48SEC EDGARUnregistered sale of shares
- 49
- 50SEC EDGAREntered a material agreement
- 51SEC EDGAROther events
- 52NasdaqNasdaq calendar
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64